Disease Model Development for Complement System Rare Diseases
Protheragen develops advanced disease modeling systems for complement system rare disorders research, employing cutting-edge technologies to replicate pathological mechanisms with high precision, thereby supporting preclinical investigations and therapeutic development processes.
Overview of Complement System Rare Disease Pathobiology and Model Development
The complement system serves as a fundamental effector mechanism of innate immunity, executing essential functions in pathogen elimination and physiological regulation. Dysregulated activation of this cascade – whether through genetic predisposition or acquired triggers – contributes to the pathogenesis of multiple rare disorders by inducing inflammatory tissue damage. Recent scientific advances have substantially clarified the dual roles of complement activation in both genetically defined and sporadic rare diseases, creating new therapeutic opportunities through targeted pathway modulation.
These conditions are typified by heterogeneous genetic variants and immune pathway disturbances, often involving multi-layered pathophysiological interactions inadequately represented in conventional experimental systems. This translational gap underscores the critical demand for disease models that authentically simulate human biology to accelerate therapeutic discovery. Protheragen's model development platform integrates molecular profiling technologies with functional validation approaches to systematically investigate complement-driven pathology. Key capabilities include:
- Mechanistic Recapitulation: Utilization of genomic editing and primary human biospecimens to mirror disease-associated molecular signatures
- Therapeutic Development Support: Functional characterization of drug candidates across discovery phases, from target engagement studies to preclinical safety assessment
- Translational Validation: Benchmarking against clinical datasets to ensure biological relevance and predictive value
Fig1. A workflow designed for efficient ABE in iPSCs. (Nami, et al., 2021)Our Services
Protheragen's experimental model portfolio enables multidimensional investigation of complement-mediated rare diseases through integrated biological platforms. Our systems encompass cellular, organotypic, and whole-organism approaches optimized for specific research objectives, employing contemporary methodologies to achieve biologically relevant recapitulation of disease processes.
- Cellular Models
Our cellular systems facilitate mechanistic analysis of complement-related pathologies through:
- Isogenic cell line development with engineered mutations
- Primary cell isolation from disease-relevant tissues
- Patient-specific iPSC differentiation protocols
- Multicellular interaction platforms (e.g., endothelial-immune cell co-cultures)
These configurable models enable high-throughput compound screening, pathway perturbation studies, and cytotoxicity profiling under controlled microenvironments.
- 3D Organoid Platforms
We establish disease-specific organoids through:
- Adult/embryonic stem cell-derived 3D cultures
- Patient tissue-derived progenitor cell expansion
- Matrisome-optimized culture conditions
Particularly developed for hepatic complement disorders, our organoids maintain native tissue architecture and disease-associated biomarkers, permitting longitudinal assessment of therapeutic interventions in polarized cellular contexts.
- Translational Animal Models
Our in vivo systems include:
- Conditional knock-in and knock-out murine models
- Human complement component transgenic strains
- Pathophysiology-inducing pharmacological challenges
These models enable comprehensive evaluation of therapeutic candidates across pharmacokinetic, efficacy, and safety parameters within intact biological systems.
Disease-Specific Experimental Models
Protheragen specializes in developing condition-specific models for complement-mediated rare disorders. These experimental systems recapitulate disease-specific genetic profiles and phenotypic manifestations to support mechanism-driven research and therapeutic discovery.
Table 1. Representative disease-specific models we provide.
| Disease | Model Type | Key Features |
|---|---|---|
| Paroxysmal Nocturnal Hemoglobinuria (PNH) | CRISPR/Cas9 Knockout Mouse Model | Replicates PIG-A gene mutation, mimics hemolytic and thrombotic complications |
| Atypical Hemolytic Uremic Syndrome (aHUS) | Humanized Mouse Model | Transplanted human liver tissue, studies complement dysregulation and renal damage |
| C3 Glomerulopathy (C3G) | 3D Organoid Model | Derived from patient biopsies, retains genetic mutations and glomerular pathology |
| Cold Agglutinin Disease (CAD) | Co-Culture System | Combines hepatocytes and immune cells to study autoimmune hemolysis |
Why Choose Us?
- Expert Team
Our team consists of experienced scientists specializing in rare disease research, dedicated to advancing your projects with up-to-date scientific knowledge and proven methodologies.
- Advanced Technologies
We employ precision gene editing, stem cell differentiation platforms, and 3D bioprinting to develop reliable models with direct clinical applicability.
- Customized Services
Collaborating closely with clients, we design bespoke models aligned with specific research goals and biological mechanisms, delivering solutions adapted to individual requirements.
- Quality Control
Through rigorous multi-step validation processes, we ensure model reproducibility and biological accuracy, enabling consistent and trustworthy research outcomes.
FAQs
-
Q: How long does it take to develop a custom disease model?
A: Development timelines vary based on model complexity. Standard cell-based models typically require 4-6 weeks. More advanced systems, such as genetically modified animal models, may take 12-16 weeks to complete.
-
Q: Can your models be used for both research and preclinical testing?
A: Yes. Our models undergo rigorous validation for diverse applications, including mechanistic research, drug candidate evaluation, and preclinical safety assessments.
-
Q: Why are Protheragen's models more reliable?
A: Our models integrate gene editing, 3D bioprinting, and multi-tiered quality verification to ensure scientifically accurate disease replication and reproducible experimental outcomes.
-
Q: Do you provide end-to-end support?
A: Yes. We offer full-project assistance spanning project planning, model development, and experimental validation, ensuring alignment with your research objectives at every stage.
Reference
- Nami F.; et al. Fast and Efficient Generation of Isogenic Induced Pluripotent Stem Cell Lines Using Adenine Base Editing. CRISPR J. 2021;4(4):502-518.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.